Arrowhead Pharmaceuticals (ARWR) Reports Q4 Loss of $1.34
Tweet
Share
E-mailGet Alerts ARWR Hot Sheet
Price: $79.90 -2.56%
EPS Growth %: +4.8%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
CBRS, MAYS, CRMT, More
EPS Growth %: +4.8%
Financial Fact:
General and administrative expenses: 2.28M
Today's EPS Names:
CBRS, MAYS, CRMT, More
Join SI Premium – FREE
Arrowhead Pharmaceuticals (NASDAQ: ARWR) reported Q4 EPS of ($1.34), versus ($1.60) reported last year. Revenue for the quarter came in at $158.33 thousand versus the consensus estimate of $382 thousand.
For earnings history and earnings-related data on Arrowhead Pharmaceuticals (ARWR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- EU approves Arrowhead's plozasiran for rare triglyceride disorder
- Green Dot and CommerceOne shareholders approve acquisition deal
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
